no desc

Agomelatine in GAD: MoA

Anxiety disorders are a diverse assemblage of conditions that have a serious and negative impact on quality of life. The most common class of anxiety disorder is GAD (generalized anxiety disorder), which unfortunately is becoming more prominent amid the current COVID pandemic.

GAD is generally treated through either cognitive-behavioural therapy or medication. However, widely used drugs like benzodiazepines and serotonin reuptake inhibitors have adverse effects.

Agomelatine exerts its anxiolytic actions by mechanisms clearly distinct from those of other agents currently employed for the management of GAD.

This review aims to shed light on agomelatine’s mechanism of action in treating GAD.

Agomelatine displays a novel and fundamentally different mechanism of anxiolytic action as compared to all other classes of medication used to treat GAD, this explains its therapeutic success and minimal adverse side effects.

TKnow more : Clik here

Barzilay R, Moore TM, Greenberg DM, et al. Resilience, COVID-19-related stress, anxiety and depression during the pandemic in a large population enriched for healthcare providers. Transl Psychiatry 2020; 10: 291. - PMC - PubMed

SCAC 05/23 CNS 018 MPAD-For the exclusive use of health professional
Background Vimeo Live Event

Keep up to date with our content

Subscribe to our newsletter so that you are always up to date with the news.

You can unsubscribe at any time by clicking on the link in our emails.
SERVIER CENTRAL AMERICA AND THE CARIBBEAN, S.A.Edificio Dream Plaza, Costa Del Este, Ciudad de Panamá, Panamá+507-301-0227Todo el contenido de este sitio web, es sólo para los profesionales de la salud y un uso interno del evento.
LogoCopyright © 2022 Servier University by SERVIER CENTRO AMÉRICA Y EL CARIBE, S.A.